MedTrace Logo

Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

NCT05141305 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2024-04-30

No results posted yet for this study

Summary

The trial is a phase 3, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled design. Patients with acute ischemic stroke due to anterior circulation large vessel occlusion within 4.5-24 hours from last known well (including wake-up stroke and unwitnessed stroke) will be randomized 1:1 to 0.25mg/kg intravenous tenecteplase or standard medical treatment.

Conditions

  • Ischemic Stroke, Acute

Interventions

DRUG

tenecteplase (0.25 mg/kg, Max 25 mg)

tenecteplase (0.25 mg/kg) is being used.

DRUG

standard medical treatment

Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yongjun Wang, MD, PhD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-19
Primary Completion
2024-01-29
Completion
2024-02-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05141305 on ClinicalTrials.gov